D
Duquesne Family Office LLC
+ HoldingPURR
+9.52%
3M Return
$12.250
+0.675 (+5.51%)收盘时
Loading chart…
- High
- 12.620
- Open
- 12.185
- VWAP
- 12.03
- Vol
- 40.61M
- Mkt Cap
- —
- Low
- 11.220
- Amount
- 488.48M
- EV/EBITDA, TTM
- 0.83
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
AI analysis of Hyperliquid Strategies Inc (PURR)
buyHyperliquid Strategies Inc (PURR) is a good buy right now due to its recent performance and strong financial indicators. The current price is $11.61, with a 1-year change of +821.43%, reflecting significant growth. Additionally, the RSI is at 66.679, indicating strong momentum. The main risk is the negative net income reported in Q1 2026, which was -1212921000.00 USD, but the company has shown recovery in subsequent quarters, with a net income of 421535000.00 USD in Q4 2026.
估值指标
The current forward P/E ratio for Hyperliquid Strategies Inc (PURR) is 0.00, compared to its 5-year average forward P/E of .
Whales holding PURR
事件时间线
资讯
9.508-30NASDAQ.COMHyperliquid Strategies Reports Strong Earnings, Stock Surges
9.508-30FoolHyperliquid Strategies Stock Sees Major Volatility and Gains
8.508-28FoolTrump's Mention of HYPE Token Drives Record High
9.508-27PRnewswireHyperliquid Strategies Reports Strong Financial Results and Ecosystem Growth
9.508-27NewsfilterHyperliquid Strategies Reports Strong Financial Results and Ecosystem Growth
PURR FAQ — answered by Alphio AI
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. It operates in the Technology sector.
Hyperliquid Strategies Inc (PURR) is a good buy right now due to its recent performance and strong financial indicators. The current price is $11.61, with a 1-year change of +821.43%, reflecting significant growth. Additionally, the RSI is at 66.679, indicating strong momentum. The main risk is the negative net income reported in Q1 2026, which was -1212921000.00 USD, but the company has shown recovery in subsequent quarters, with a net income of 421535000.00 USD in Q4 2026.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。